Currently, available antibodies such as 8F1 cannot discriminate between these isoforms and thus cannot guide therapeutic decision-making regarding cisplatin combined therapy in patients with non-small-cell lung cancer; this requires specific detection of the unique functional ERCC1-202 isoform [26]. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.